Plus Therapeutics at the 40th SITC Annual Meeting
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company, recently made significant strides in the treatment of central nervous system (CNS) cancers. The company announced they would be partaking in the Society for Immunotherapy of Cancer (SITC) Annual Meeting and the Melanoma Research Foundation Brain Metastases Summit 4.0. These events take place in Alexandria, VA, on November 9, 2025, providing a notable platform to present their pioneering research. Dr. Andrew Brenner, an esteemed Professor of Medicine, will delve into their REYOBIQ and ReSPECT-LM clinical trial findings.
ReSPECT-LM Phase 1 Trial Breakthroughs
The clinical results from the ReSPECT-LM Phase 1 trial revealed substantial promise. At a previous conference focused on CNS metastases, the datum gleaned from the trial indicated impressive benefits:
Clinical Benefits of REYOBIQ
REYOBIQ exhibited a clinical benefit rate exceeding 75% across critical outcome measures. Moreover, advances in RNA sequencing and notable reductions in circulating tumor cells were consistent with cell death from the treatment. Notably, the trial reported no dose-limiting toxicities leading to a favorable safety profile, which is crucial for ongoing research.
Insights from the Ongoing Research
Dr. Brenner articulated optimism surrounding the ReSPECT-LM outcomes, emphasizing the unmet need in treating leptomeningeal metastases (LM). The lack of approved therapies in this domain underscores REYOBIQ's potential, particularly as the treatment showcased excellent tolerance at significantly higher doses compared to existing benchmarks. Encouragingly, REYOBIQ has also received FDA Fast Track and Orphan Drug Designation, a testament to its potential in addressing this urgent medical need.
The Challenge of Leptomeningeal Metastases
Leptomeningeal metastases are a severe complication associated with advanced cancer, impacting about 5% of metastatic cancer patients. It is often formed as a result of breast cancer, lung cancer, and melanoma. Unfortunately, the prognosis remains grim, with typical survival rates ranging from 2 to 6 months due to an evident lack of effective treatment options. Hence, innovative therapies like REYOBIQ are crucial.
Innovation Behind REYOBIQ™
REYOBIQ (rhenium Re186 obisbemeda) represents a breakthrough in injectable radiotherapy designed specifically for CNS tumors. Its formulation aims to deliver high doses directly at tumor sites safely and effectively. The use of Rhenium-186 allows for targeted destruction of cancerous tissue while minimizing risks associated with off-target irradiation. Trials are also evaluating its efficacy for recurrent glioblastoma and pediatric brain cancers, thus significantly advancing therapeutic options.
The Role of CNSide Diagnostic, LLC
Additionally, CNSide Diagnostics, LLC, a subsidiary of Plus Therapeutics, is making waves with diagnostic innovations. Their CNSide® tests are essential for identifying tumor cells in the cerebrospinal fluid, which is vital for managing patients with leptomeningeal metastases, showing the company's commitment to advancing both treatment and diagnostic capabilities in CNS cancers.
About Plus Therapeutics
Based in Houston, Texas, Plus Therapeutics focuses on developing targeted therapies aimed at difficult-to-treat CNS cancers. Through innovative approaches that combine targeted radiation and local drug delivery, the company is working on a range of it’s product candidates, particularly emphasizing its work on leptomeningeal metastases and glioblastoma. Their proactive partnerships bolster their manufacturing and commercial potential, expanding the reach of their promising therapies.
Frequently Asked Questions
What is Plus Therapeutics focusing on?
Plus Therapeutics is prioritizing the development of targeted radiotherapeutics for CNS cancers.
What clinical trials is Plus Therapeutics conducting?
The company is conducting the ReSPECT-LM and ReSPECT-GBM trials along with several others.
What is REYOBIQ?
REYOBIQ is a novel injectable radiotherapy designed for delivering targeted radiation to CNS tumors.
How common are leptomeningeal metastases?
Leptomeningeal metastases occur in approximately 5% of cancer patients with metastasis.
What distinguishes Plus Therapeutics' approach?
They combine advanced imaging techniques with localized radiation to improve cancer treatment outcomes.
